作者
J. Wang,Z. Wang,Lin Wu,B. Li,Yin Cheng,X. Li,X. Wang,L. Han,Xinquan Wu,Yun Fan,Yang Yu,Dongqing Lv,Jianping Shi,Jian Huang,Song Zhou,Baohui Han,Guohua Sun,Qianyun Guo,Yuzhang Ji,Xiaomin Zhu,Sylvia Hu,W. Zhang,Q. Wang,Yaqi Jia,Zhaoguang Wang,Yaqi Song,Jing Wu,Meiqi Shi,X. Li,Ze‐Guang Han,Y. Liu,Zhuang Yu,Andy Liu,X. Wang,Caicun Zhou,Diansheng Zhong,Liyun Miao,Zhi Zhang,H. Zhao,Jin‐Ming Yang,Dong Wang,Y. Wang,Q. Li,Xun Zhang,Mei Ji,Zhenzhou Yang,Jiuwei Cui,B. Gao,Baoming Wang,Huan Liu,Ling Nie,Minfei He,Jin Shi,Wen Gu,Yongqian Shu,Tong Zhou,Jianxing Feng,Xiaohua Yang,Cheng Huang,Bo Zhu,Yu Yao,Yudong Wang,Xing Kang,Sheng Yao,Patricia Keegan
摘要
Toripalimab, a humanized monoclonal antibody against PD-1, was approved for treatment of previously treated advanced melanoma and nasopharyngeal carcinoma. Here, we report the results of CHOICE-01 (NCT03856411), a randomized, double-blind Phase 3 trial of toripalimab in combination first-line chemotherapy for advanced non-small cell lung cancer (NSCLC).
迟大猫
劲秉
美好乐松
科研小民工
Singularity
QOP
cdercder
昏睡的蟠桃
VDC
爱静静
MchemG
Grayball
迷人秋烟
默默地读文献
1+1
今天只做一件事
pcr163
iNk
nozero
pluto
皖公网安备34019202002308
